Oral, Direct Factor Xa Inhibitor, BAY 59-7939 [rivaroxaban], Given Once Daily in Patients Undergoing Total Hip Replacement (ODIXa-HIP)

Trial Profile

Oral, Direct Factor Xa Inhibitor, BAY 59-7939 [rivaroxaban], Given Once Daily in Patients Undergoing Total Hip Replacement (ODIXa-HIP)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2007

At a glance

  • Drugs Enoxaparin sodium; Rivaroxaban
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms OXIDa-HIP
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 18 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top